

AMC BROADGATE QUANT 1

As of 30 May 2025

OBJECTIVE

To efficiently harvest rewarded systematic risk premia in the market, while eliminating unrewarded risk exposures, allowing investors to earn higher returns per unit of risk.

INVESTMENT STRATEGY & PROCESS

The portfolio is based on Broadgate's Quantitative Multi-Factor Model. It focuses on the proper management of "factor exposures" as the main source of performance and looks through asset class decompositions to focus on underlying factor decomposition. It aims to invest in an equal-weighted portfolio of 40 equity names in developed markets, selected based on Broadgate's proprietary Multi-Factor model. The strategy aims to outperform the benchmark – MSCI World index – by following an allocation determined by the intensity of factors (Momentum, Value, Low Volatility, Quality and Growth). Factors are built in-house, using proprietary descriptors with high return explanatory powers and a unique weighting scheme that allocates dynamically among the factors. The portfolio is rebalanced monthly, and the methodology is continuously reviewed by Broadgate's quant research team.

PRODUCT CHARACTERISTICS

Product	> AMC Broadgate Quant 1
ISIN	> FRELU0003488
Issuer/ Guarantor	Exane Solutions Luxembourg (SA) / BNP Paribas Moody's: Aa3; S&P: A+; Fitch AA-
Underlying	> Broadgate Quant 1 Dynamic Portfolio
Actively Managed	Yes, by Broadgate Advisers
Maturity	> Open-End
Denomination	▶ 1'000 USD
Currency	> USD
Total Management Fees	 1.25% p.a. (i.e 0.25% to Exane Solutions and 1.00% to Broadgate Advisers) + 10% Performance fees based on high watermark over an initial hurdle of 107%
Liquidity	➤ Daily
Pricing Publication	> Telekurs, Bloomberg
NAV	➤ USD 1152.38 (as of May 30 th , 2025)

AMC Manager Comment

The strategy was up by 7.6% in May while MSCI World was up by 5.7%.

Attribution: Last month *Energy* was down -0.4%. All other sectors were up between 0.9% to 2.4%. Broadgate Quant mandate outperformed the market by 1.9%, due to positive selection (1.2%) and allocation (0.7%) effects.

Positive selection mainly from Healthcare: overweight *Orion* up 8.2%, but underweight *Eli Lilly* down -17.8%; Information Technology: underweight *Apple* down -5.4%, but overweight *Applovin* up 45.9%; and Materials: *Fresnillo* up 20.1%, *Wheaton Precious Metals* 13.2% and *Newmont* 8.9%. Positive allocation mainly due to overweight *Information Technology* and underweight *Consumer Staples*.

Factor Sensitivity (Beta): The current top style exposures are, by order, Quality, Growth and Momentum.

HISTORICAL PERFORMANCE



Performance snapshot of the share class - Actual 15.09.21 -30.05.25

		Quant 1*	World
Performance (%)	1 Month	7.62	5.69
	3 Months	4.81	1.53
	YTD	3.40	4.20
	Since Inception	15.24	23.52
Risk (ex-post)	Annualized Volatility (%)	18.33	17.46
	Correlation	0.89	
	Tracking Error (%)	8.32	
	Beta	0.94	
Risk/Return	Sharpe Ratio	0.28	0.38
	Information Ratio	-0.17	

AMC Broadgate Quant 1

Broadgate MSCI



AMC BROADGATE QUANT 1

As of 30 May 2025









Portfolio Contribution

Best Performers


Components	MTD Performance
APPLOVIN CORP-CLASS A	45.93%
BROADCOM INC	25.77%
NVIDIA CORP	24.06%
FRESNILLO PLC	20.10%
ARISTA NETWORKS INC	19.39%
AJ BELL PLC	18.06%
MICROSOFT CORP	16.68%
ASML HOLDING NV	16.33%
DECKERS OUTDOOR CORP	14.91%
ADYEN NV	14.81%

Worst Performers


Components	MTD Performance
COPART INC	-15.65%
BONESUPPORT HOLDING AB	-11.90%
MERCK & CO. INC.	-9.81%
KONAMI GROUP CORP	-9.51%
HEMNET GROUP AB	-6.82%
NOVARTIS AG-REG	-6.70%
TRUECALLER AB-B	-5.08%
DOLLARAMA INC	-4.84%
AUTO TRADER GROUP PLC	-4.45%
ELECTRONIC ARTS INC	-2.22%

Portfolio Allocations

Breakdown by Geography



Breakdown by Sector



For more Information:

Broadgate Advisers

Tel:+41 (0)22 316 0060 Email: Quant1@broadgate.ch Internet: https://broadgateadvisers.com/

BNP Paribas Suisse SA

Email: joris.maillet@bnpparibas.com

This document/communication may contain "Research" as defined under MFID II unbundling rules; any such Research is intended either (i) for those firms who are in scope of the MFID II unbundling rules and have signed up to a BNP Paribas Global Markets Research package, or (iii) for firms that are out of scope of the MFID II unbundling rules and therefore are not required to pay for Research under MFID II. Please note that it is your firm's responsibility to ensure that you do not view or use any Research in this document. If your firm has not signed up to a BNP Paribas Global Markets Research package, unless your firm is out of scope of the MFID II unbundling rules. This document may also be regarded as a minor non-monetary benefit (MNMB) and it is your firm's responsibility to consider its own regulatory obligations in relation to inducements and accepting MNMBs. This document is COMFIDENTIAL AND FOR DISCUSSION PURPOSES ONLY; it constitutes an arketing communication and has been prepared by a Sales and Marketing function within BNP Paribas and your asks and part of any offer to sell or issue and is not a solicitation of any offer to purchase any financial instrument, nor shall it or any part of the fort first is subsidiaries or statistic collectively "or "Or "BNP Paribas".) As confidential document it is submitted to selected recipients only and its relation to the second part of any offer to purchase any financial instrument, nor shall it or any part of the fact of its distribution form any part of any offer to sell or issue and is not a solicitation of any offer to purchase any financial instrument, nor shall it or any part of the or the fact of its distribution form any part of any offer to sell or issue and is not a solicitation of any offer to purchase any financial instrument, nor shall it or any part of the fact of the fact of the control or partial solicitation of any offer to purchase any financial instrument, nor any operation because of the solicitation of any offer to purchase any financial instrume